Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al.
Wahl
Denis
D
Lecompte
Thomas
T
Bounameaux
Henri
H
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D001241:Aspirin / Q000627:therapeutic use*; D006801:Humans; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D017152:Antibodies, Antiphospholipid; D001241:Aspirin